Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers M > Headlines for MannKind Corp. > News item |
MannKind rated outperform by Leerink Swann
MannKind Corp. received an initial rating of outperform from Leerink Swann & Co. analyst William Tanner. He predicted MannKind's Technosphere inhaled insulin product, currently in phase-three clinical trials, will position the corporation well for partnering opportunities.
Shares of the Valencia, Calif.-based biotechnology company were up $0.75, or 6.76%, at $11.85 on volume of 242,986 shares versus the three-month running average of 215,467 shares.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.